Bayer partners with Arogya Finance to provide Eylea Easy Pay Program in India

Mumbai, December 21, 2020: Bayer today, announced its collaboration with social healthcare venture Arogya Finance to introduce the Eylea Easy Pay Program in India to provide flexible and affordable payment solutions to help patients in India access Eylea (aflibercept solution) treatment. Through this partnership, Bayer and Arogya Finance have increased the accessibility of the innovative treatment solutions, thus reducing the immediate financial burden on patients and their families. These financing solutions will be available across the country. Centers in states like Maharashtra, Delhi, Karnataka, Bengal, Kerala, Tamil Nadu Uttar Pradesh, to name a few, will offer this program to their patients.


Today, diabetes affects close to 67 million people in India,  and approximately 3-4.5 million of them develop visual impairments  due to diabetic eye diseases, such as Diabetic Macular Edema (DME). Bayer’s Eylea is used for the treatment for both Wet AMD, which affects the elderly population and DME, which affects diabetics, and is administered via an injection directly into the eye. Since Eylea is an ongoing treatment for chronic eye conditions, treatment adherence is important. 


Bayer launched the “Eylea 4 U” Patient Assistance Program in 2020 with the objective of improving access and adherence to the treatment by Indian patients. In continuation with this aim, Bayer and Arogya Finance have collaborated to tackle the central issue of patient adherence by reducing the upfront financial burden of treatment that usually impacts the patient and their families. The benefits of this collaboration include lower up-front payments, flexibility in payment options and easy equated monthly installment (EMI). With treatment accessibility and patient centricity as the key focus, Eylea Easy Pay aims to help patients and caregivers focus on effective management of the condition.


“At Bayer, we have always been committed to a Patient First approach to treatment. We aim to provide effective and innovative solutions to address unmet health needs, while supporting our patients in accessing and adhering to their treatment plans. By collaborating with Arogya Finance, we extend our commitment to delivering solutions to improve and maintain vision, to support patients on their journey to better health,” said Manoj Saxena, Managing Director, Bayer Zydus Pharma & Country Division Head South Asia.


Commenting on the partnership, Jose Peter, Co-founder and CEO, Arogya Finance said, “We at Arogya Finance work to establish an ecosystem which benefits the patients and their caregivers through ease of financing solutions for treatment. Arogya Finance has partnered with Bayer so we can work together to deliver flexible financing solutions that support increased patient access to treatment to enable a greater number of individuals across India to benefit from the innovative therapy.”


Dr. Shobhit Chawla, Sr. Vitreo Retina Consultant at Prakash Netra Kendra in Lucknow and President of Vitreo Retina Society of India (VRSI) commented, “There is an urgent need to drive attention towards avoidable vision loss in India. Preventive care, diagnosis and adherence to long term treatment has been impacted during the pandemic. We have observed a drop in patient adherence to treatment for Wet AMD and DME, often due to financial constraints. This program offered by Arogya Finance in collaboration with Bayer will defiantly help patients to maintain good treatment compliance, thus ensuring they can access the best treatment options available. Such programs enable patients and their caregivers to focus on maintaining health with greater confidence and convenience, while reducing the financial burden.”



1.Das T, Aurora A, Chhablani J, Giridhar A, Kumar A, Raman R, et al. Evidence-based review of diabetic macular edema management: Consensus statement on Indian treatment guidelines. Indian J Ophthalmol 2016;64:14-252013; 75-79.



3.Baumal C. Wet Age-Related Macular Degeneration: Treatment Advances to Reduce the Injection Burden. Macular Degeneration, Volume 26, Issue 5.


4.Das T, Aurora A, Chhablani J, Giridhar A, Kumar A, Raman R, et al. Evidence-based review of diabetic macular edema management: Consensus statement on Indian treatment guidelines. Indian J Ophthalmol 2016;64:14-252013; 75-79.




About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of € 43.5 billion. Capital expenditures amounted to € 2.9 billion and R&D expenses to € 5.3 billion. For more information, go to


About Arogya Finance

Arogya Finance is a social healthcare venture providing medical loans for medical treatment using a new model for measuring credit worthiness and risk. Launched in 2011, Arogya Finance has partnered with 50 hospitals and healthcare service providers across India and processed 320 loans. They offer loans to the traditionally ‘un-bankable,’ involving risk assessment tools that allows them to finance outside the formal banking system. For more information, go to

Media Contact

Sophia Gonsalves
Communications, Bayer Zydus Pharma Ltd.


Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports, which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.